Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating belimumab as an additional treatment for adults with interstitial lung disease ILD linked to connective tissue diseases CTDs such as rheumatoid arthritis, systemic lupus erythematosus, and others. ILD leads to lung inflammation and stiffness, causing symptoms like shortness of breath and cough, which significantly reduce quality of life and are the main cause of death in these patients. This study aims to see if belimumab combined with standard therapy can stabilize or improve lung function and ILD symptoms while maintaining an acceptable safety profile. Participants are randomly assigned to receive either belimumab or a placebo, both alongside standard therapy. Belimumab is given by subcutaneous injection. The study lasts for 52 weeks with treatment and monitoring occurring throughout this period. The primary measurement is the change in lung function, specifically forced vital capacity FVC, from baseline to week 52. Various secondary measures assess lung symptoms, fatigue, quality of life, lung imaging, and safety outcomes. During the study, participants will have assessments at baseline and week 52 including lung function tests, symptom questionnaires, and imaging scans. Researchers will track changes in lung capacity, disease progression, symptom severity, fatigue, and medication use. Safety monitoring continues up to week 60 to record adverse events and hospitalizations related to respiratory issues. Participants will be involved in regular visits for evaluation and medication administration over the course of the year-long study.
Actively Recruiting
Researchers are evaluating the efficacy and safety of belimumab compared to placebo, both given alongside standard therapy, for adults with systemic sclerosis associated interstitial lung disease SSc-ILD. The study aims to assess how belimumab affects lung function and other disease features such as skin thickening and symptoms like fatigue that influence quality of life. Participants will be randomly assigned to receive either belimumab or a placebo, both in addition to their usual therapy. Belimumab is given by subcutaneous injection. The study measures various health outcomes at baseline and after 52 weeks, including lung capacity, skin condition, fatigue, and disease progression. Throughout the study, participants will undergo scans, lung function tests, skin assessments, and questionnaires about symptoms and quality of life. Researchers will monitor adverse events and disease markers to evaluate treatment impact and safety over the 52-week period.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a multi-site, prospective, observational cohort study focusing on nulliparous women carrying a single fetus during pregnancy. The study aims to evaluate blood-based biomarkers and retinal imaging to predict pregnancy complications such as preeclampsia, fetal growth restriction, and gestational diabetes. This research is designed to improve risk evaluation and management of these conditions during pregnancy. Participants will not receive any treatment as this is an observational study. The research includes two parts one cohort focuses on developing and validating blood-based biomarkers at different gestational timepoints, while the other develops and validates a retinal imaging algorithm for predicting preeclampsia. These assessments occur from early pregnancy through approximately four weeks after delivery. During the study, participants will provide blood samples and undergo ocular imaging. Data on pregnancy outcomes and biospecimen samples will be collected and stored in a biobank. Researchers will analyze these data to identify risk cut-offs and validate biomarker accuracy. The total participation duration spans from enrollment in early pregnancy until about one month postpartum, with ongoing monitoring of pregnancy outcomes and retinal imaging results.
Actively Recruiting
Healthy Volunteer
Researchers are studying the Caris Biorepository, a project designed to collect and store high-quality biological specimens and related clinical data to support research aimed at advancing precision medicine and improving patient care. This observational study focuses on gathering samples and information from various sources, including healthy individuals and cancer patients, to help understand disease treatments and clinical outcomes. The biorepository includes samples from different donor groups, such as those with no disease, treatment-nave patients with new solid tumors, individuals at higher risk for cancer, patients with advanced cancer, and those with a history of cancer but no active disease. The project aims to maintain molecular integrity and clinical relevance of these specimens while providing access to researchers and collaborators for drug development, clinical trials, and healthcare policy enhancements. Participants provide informed consent and contribute biological samples and clinical data that are securely stored and shared for research purposes. The study measures include ensuring specimen quality and relevance over 35 years and facilitating specimen release for testing. Laboratory testing will be conducted throughout the study duration. The project supports long-term research collaboration and aims to impact patient outcomes and treatment practices over time.
Actively Recruiting
Rheumatoid arthritis RA is a chronic autoimmune disease where the immune system attacks joint tissue, causing pain, swelling, and stiffness. This condition affects about 1.5 million people in the US and can lead to serious joint damage if untreated. Access to specialized rheumatology care is limited, especially in rural areas like northern New York, making it difficult for many patients to receive proper treatment. This trial evaluates whether trained primary care providers PCPs can manage stable RA patients as effectively as rheumatologists, potentially improving care access in underserved regions. In this randomized controlled trial, patients with stable RA will be assigned to either continue care with their usual rheumatologist or receive care from a PCP who has completed a structured RA training program. Nine PCPs underwent training including lectures, case studies, and exams, with ongoing monthly case reviews with rheumatology specialists. The study will enroll up to 100 participants and follow them for one year, comparing the two care models. The intervention group receives RA management from trained PCPs, while the control group continues usual care in a rheumatology clinic. Participants will attend visits at screeningbaseline, 6 weeks, 12 weeks, 26 weeks, 40 weeks, and 52 weeks. Assessments include standard RA activity measures like MDHAQ, joint counts, disease activity scores DAS28, CDAI, SDAI, glucocorticoid exposure, patient-reported outcomes, and medical records review. The main outcome is change in DAS-28 at 6 and 12 months. This study will monitor patient status and safety throughout the year to evaluate if PCP-led care can maintain disease control and improve access for rural RA patients.
Actively Recruiting
Healthy Volunteer
Postural instability caused by vestibular dysfunction can affect daily activities. Researchers are evaluating a new training method called concurrent headshake and weight shift training Concurrent HS-WST using virtual reality to improve balance and vestibular function in healthy young adults. This approach aims to engage sensory reweighting and enhance vestibular reflexes more effectively than traditional methods. The study is conducted by Clarkson University and focuses on healthy adults aged 18 to 35 years. Participants will undergo vestibular activation training involving headshake and weight shift exercises while wearing a virtual reality headset. The study uses a randomized crossover design where one group receives the training for 6 days followed by a 4-day break and then no training for 6 days, while the other group follows the reverse sequence. Safety measures include an overhead harness and a spotter to prevent falls during training. During the two-week study, participants will perform postural assessments, reactive balance tests after mechanical perturbations, and headshake activities. Researchers will measure vestibulo-ocular reflex VOR gain, eye movement variability, electromyography EMG amplitude and timing, balance scores, and sensory ratios. These evaluations will help understand the effects of the training on vestibular and postural control. Participants adherence and safety will be closely monitored throughout the study.
Actively Recruiting
This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.
Actively Recruiting
This research aims to evaluate an online relationship program designed for couples where one or both partners are in recovery from substance misuse. The study focuses on strengthening romantic relationships and improving individual well-being by addressing common issues like relationship conflict and distress that can interfere with substance use disorder SUD recovery. The program is based on Integrative Behavioral Couple Therapy IBCT, adapted for digital delivery and tailored specifically to the challenges faced by couples in recovery. Couples in this study will participate in approximately 8 to 10 hours of online content delivered over 5 to 8 weeks. The program includes sections called Observe, Understand, and Respond, which guide partners through identifying relationship problems, understanding core issues, and developing strategies to improve communication and reduce stress. The content features videos, audio, graphics, interactive feedback, and examples of diverse couples. Couples also receive up to five 20-minute coaching calls conducted via phone or Zoom to support their progress throughout the program. Participants will complete online surveys before starting and after finishing the program to assess changes in relationship satisfaction, conflict, emotional trust, and recovery-related factors. Researchers will monitor progress during the approximately 8-week intervention period. The study provides 200 per couple for completing surveys. Throughout participation, couples will have access to digital content and scheduled coaching, aiming to support both relationship and individual recovery. The total involvement includes program completion and follow-up assessments.
Actively Recruiting
This trial focuses on participants with autoimmune and inflammatory conditions who have previously taken part in a Novartis study involving secukinumab. It aims to evaluate the long-term safety of secukinumab in those who continue to benefit from the treatment but cannot access the marketed version. The study is a Phase 4, open-label extension designed to provide ongoing assessment of this medication. Participants will receive secukinumab injections under the skin at doses of 75 mg, 150 mg, or 300 mg every four weeks, depending on their previous treatment dose in the parent trial. Pediatric dosing will be limited according to weight categories and prior evaluated maximum doses. Investigators can adjust doses based on clinical needs and health authority guidance. This study involves a single group receiving secukinumab with no placebo or comparator. During the study, participants will be monitored for up to two years to assess the occurrence of any adverse or serious adverse events. The trial will involve regular evaluations to track the participants safety while continuing secukinumab treatment. The total duration for participation can extend until the study ends in 2030, with ongoing safety assessments throughout this period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called ianalumab VAY736 given as a monthly injection under the skin for one year. This study focuses on adults with Sjgrens disease who experience a high level of symptoms. The trial is a Phase III, double-blind, randomized study comparing ianalumab to a placebo to assess how well it reduces symptoms and improves quality of life. Participants will receive either 300 mg of ianalumab or a placebo once a month by subcutaneous injection for 52 weeks. The study has two groups one receiving the active drug and the other receiving placebo injections. The aim is to see how ianalumab affects dryness symptoms and other disease-related measures compared to placebo during the treatment period. During the study, participants will be closely monitored with various assessments including symptom scores, saliva flow tests, and quality of life questionnaires over the 52 weeks. Researchers will track changes in oral dryness and other symptoms, fatigue, and overall well-being. Safety and side effects will be monitored throughout the treatment period, and participants will have regular visits for evaluations.